Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Verdiva Bio has raised $411.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Verdiva Bio's investors include General Atlantic, RA Capital Management, Lilly Asia Ventures, OrbiMed, LYFE Capital.
Verdiva Bio is headquartered in London, United Kingdom.
Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.
Verdiva Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Verdiva Bio — Funding & Investors." VCBacked, January 9, 2025, https://www.vcbacked.co/company/verdiva-bio. Accessed July 28, 2026.
VCBacked. (2025). Verdiva Bio — Funding & Investors. Retrieved July 28, 2026, from https://www.vcbacked.co/company/verdiva-bio
{{cite web |title=Verdiva Bio — Funding & Investors |url=https://www.vcbacked.co/company/verdiva-bio |website=VCBacked |access-date=July 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated